CompanyGraph
Cosmos Pharmaceutical Corp.
3349 · Japan
Price data from its CSMYF listing on OTC, quoted in USD
cosmospc.co.jpFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleMarket cap is $3.74B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.06: safe zone
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.39%Above 5Y avg (0.75%)
Annual Rate
JPY 89.00Paid semi-annual
Payout Ratio
20.3%Sustainable
Payback Period
0.5 yr
Next Ex-Dividend
Nov 27, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
591.97BJPY3.74B · vs all stocks (USD)
Trailing P/E
15.92xvs Pharmaceutical Retailers peers
Revenue (TTM)
1.10TJPY6.94B · vs all stocks (USD)
Profit Margin
2.91%vs Pharmaceutical Retailers peers
Beta
0.1500xvs all stocks
52-Week Change
-33.17%vs all stocks
Forward Annual Dividend Yield
1.39%vs all stocks
Market Capitalization
591.97BJPY3.74B · vs all stocks (USD)
Enterprise Value
524.86BJPY3.31B · vs all stocks (USD)
Trailing P/E
15.92xvs Pharmaceutical Retailers peers
Forward P/E
17.63xvs Pharmaceutical Retailers peers
PEG Ratio
0.6363xPrice to Sales (TTM)
0.4640xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
1.80xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.4770xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
7.89xvs Pharmaceutical Retailers peers
Profit Margin
2.91%vs Pharmaceutical Retailers peers
Operating Margin
3.53%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
4.67%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
11.84%vs Pharmaceutical Retailers peers
Revenue (TTM)
1.10TJPY6.94B · vs all stocks (USD)
Revenue per Share (TTM)
13.87KJPYUpdated Aug 20, 2026Quarterly Revenue Growth
11.60%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
229.68BJPY1.45B · vs all stocks (USD)
EBITDA (TTM)
65.64BJPY414.30M · vs all stocks (USD)
Net Income (TTM)
32.05BJPY202.26M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.70%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
58.79BJPY371.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-18.19BJPY-114.80M · vs all stocks (USD)
Forward Annual Dividend Rate
89.00JPYUpdated Aug 20, 2026Forward Annual Dividend Yield
1.39%vs all stocks
Trailing Annual Dividend Rate
82.00JPYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.28%vs all stocks
5-Year Average Dividend Yield
0.75%vs all stocks
Payout Ratio
20.28%vs Pharmaceutical Retailers peers
Revenue
1.01TJPYFY2025 · May 31, 2025Cost of Goods Sold
798.11BJPYFY2025 · May 31, 2025Gross Profit
213.28BJPYFY2025 · May 31, 2025Operating Income
40.40BJPY255.01M · vs all stocks (USD)
Pre-tax Income
42.37BJPYFY2025 · May 31, 2025Income Tax Expense
11.39BJPYFY2025 · May 31, 2025Net Income
30.98BJPYFY2025 · May 31, 2025EBIT
42.63BJPYFY2025 · May 31, 2025EBITDA (Income Statement)
65.64BJPYFY2025 · May 31, 2025Non-operating Interest Income
48.00MJPYFY2025 · May 31, 2025Non-operating Interest Expense
254.00MJPYFY2025 · May 31, 2025Basic Shares Outstanding
79.26MSharesFY2025 · May 31, 2025Diluted Shares Outstanding
79.26MSharesFY2025 · May 31, 2025Preferred Stock Dividends
0.00JPYFY2025 · May 31, 2025Operating Cash Flow
41.68BJPYFY2025 · May 31, 2025Free Cash Flow
-11.64BJPYFY2025 · May 31, 2025Cash & Cash Equivalents (End of Period)
57.04BJPYFY2025 · May 31, 2025Starting Profit (CF Statement)
42.37BJPYFY2025 · May 31, 2025Other Non-cash Items
5.68BJPYFY2025 · May 31, 2025Change in Accounts Receivable (CF)
-192.00MJPYFY2025 · May 31, 2025Change in Other Assets/Liabilities
-6.18BJPYFY2025 · May 31, 2025Capital Expenditures
-53.33BJPYFY2025 · May 31, 2025Other Investing Activity
-2.12BJPYFY2025 · May 31, 2025Net Investing Cash Flow
-55.45BJPYFY2025 · May 31, 2025Long-term Debt Issuance
20.00BJPYFY2025 · May 31, 2025Long-term Debt Payments
-5.08BJPYFY2025 · May 31, 2025Common Stock Repurchase
-2.00MJPYFY2025 · May 31, 2025Common Dividends Paid
-4.96BJPYFY2025 · May 31, 2025Other Financing Charges
-2.00MJPYFY2025 · May 31, 2025Net Financing Cash Flow
9.96BJPYFY2025 · May 31, 2025Shares Outstanding
79.26MSharesUpdated Aug 20, 2026Float Shares
39.41MSharesUpdated Aug 20, 2026% Held by Insiders
55.27%vs all stocks
% Held by Institutions
32.38%vs all stocks
Total Cash (MRQ)
61.34BJPY387.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
773.95JPYUpdated Aug 20, 2026Total Debt (MRQ)
78.48BJPY495.31M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2766xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
0.7680xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
3.58KJPYUpdated Aug 20, 2026Total Assets
524.75BJPY3.31B · vs all stocks (USD)
Total Current Assets
165.62BJPYFY2025 · May 31, 2025Total Liabilities
267.29BJPYFY2025 · May 31, 2025Total Non-current Assets
359.13BJPYFY2025 · May 31, 2025Total Non-current Liabilities
46.61BJPYFY2025 · May 31, 2025Total Current Liabilities
220.68BJPYFY2025 · May 31, 2025Cash & Cash Equivalents
57.04BJPYFY2025 · May 31, 2025Accounts Receivable
761.00MJPYFY2025 · May 31, 2025Inventory
92.32BJPYFY2025 · May 31, 2025Accounts Payable
177.13BJPYFY2025 · May 31, 2025Short-term Debt
7.94BJPYFY2025 · May 31, 2025Other Current Liabilities
1.82BJPYFY2025 · May 31, 2025Long-term Debt
42.02BJPYFY2025 · May 31, 2025Other Non-current Liabilities
434.00MJPYFY2025 · May 31, 2025Common Stock (Book)
4.18BJPYFY2025 · May 31, 2025Retained Earnings
248.31BJPYFY2025 · May 31, 2025Total Shareholders' Equity
257.46BJPY1.63B · vs all stocks (USD)
Treasury Stock
227.00MJPYFY2025 · May 31, 202552-Week Low
5.62KJPYUpdated Aug 20, 202652-Week High
9.69KJPYUpdated Aug 20, 202652-Week Change
-33.17%vs all stocks
Beta
0.1500xvs all stocks
50-Day MA
6.31KJPYUpdated Aug 20, 2026200-Day MA
6.78KJPYUpdated Aug 20, 2026Avg 10-Day Volume
335.10KSharesUpdated Aug 20, 2026Avg 30-Day Volume
441.03KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
404.22JPYUpdated Aug 20, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Near All-Time Low With Profitability
Within 5% of its all-time low, profitable three years, and equity-funded.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.12Receivables vs revenue divergence: 5.57
Financial Health
Altman Z-Score 4.06: safe zoneNotable
Altman Z-Score: 4.06
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Market cap is $3.74B, above the global median of $1.15BNotable
Market cap (USD): 3,736,293,708.538Global Median: 1,146,734,693.424
Revenue is $6.94B, above the global median of $520.53MNotable
Revenue (USD): 6,940,128,454.22Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Group 1 Automotive Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
Inchcape plc
Tier 1FlowUnit ReplicationInterfaceRisk
The Geo Group, Inc.
Tier 1FlowUnit ReplicationRuleProduction
Xiamen C&D Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Zhongsheng Group Holdings Limited
Tier 1FlowUnit ReplicationInterfaceRisk
Ollie's Bargain Outlet Holdings Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Bright Horizons Family Solutions Inc.
Tier 1FlowUnit ReplicationInterfaceSenseMaking
Jumbo S.A.
Tier 1FlowUnit ReplicationInterfaceRisk
Sumber Alfaria Trijaya Tbk
Tier 1FlowUnit ReplicationInterfaceProduction
Asbury Automotive Group Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
Hanyu Group Joint Stock Limited
5 interpretationsHigh Retained Earnings With Profitability And EquityRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Amoy Diagnostics Co., Ltd.
5 interpretationsHigh Retained Earnings With Profitability And EquityRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Hebei Keli Automobile Equipment Co., Ltd.
5 interpretationsHigh Retained Earnings With Profitability And EquityRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity